Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1893-33-0
Molecular formula
C21H30FN3O2
Molecular weight
375.5 g/mol
Drug class
Butyrophenone antipsychoticserotonin 5-HT2A and dopamine-receptor antagonist
Mechanism of action
Binds mainly to 5-HT2A receptors, with high affinity for D4 and moderate affinity for D2/D3 and other receptors. Its antipsychotic activity reflects modulation of central serotonergic and dopaminergic signalling.
Indications / reported uses
Treatment of schizophrenia and selected chronic psychotic disorders in countries where pipamperone is authorised.
Symptomatic management of selected behavioural disturbances or aggression where covered by local product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pipamperone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pipamperone Permitted Daily Exposure (PDE) report (the Pipamperone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pipamperone Occupational Exposure Limit (OEL) report (the Pipamperone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.